Skip to main content
. 2022 Jan 6;23(1):3. doi: 10.1186/s10194-021-01377-6

Table 3.

Parameter estimates in multivariable analysis of factors associated with peripheral levels of NGF, BDNF, PGE2, and VEGF

Characteristic Coefficient P-value 95% CI for coefficient
Lower bound Upper Bound
NGF model: EM diagnosis (vs. control) -31.360 0.003 -51.683 -11.038
NGF model: EM diagnosis (vs. CM) -17.148 0.042 -33.618 -0.678
NGF model: CM diagnosis (vs. control) -12.994 0.156 -31.052 5.064
BDNF model: EM diagnosis (vs. control) -0.583 <0.001 -0.715 -0.450
BDNF model: CM diagnosis (vs. control) -0.572 <0.001 -0.690 -0.454
BDNF model: CM diagnosis (vs. EM) 0.017 0.715 -0.077 0.111
PGE2 model: EM diagnosis (vs. control) -29.284 0.011 -51.781 -6.788
PGE2 model: CM diagnosis (vs. EM) 15.324 0.086 -2.251 32.899
PGE2 model: CM diagnosis (vs. control) -14.163 0.163 -34.152 5.827
VEGF model: EM diagnosis (vs. control) 258.626 <0.001 168.119 349.132
VEGF model: CM diagnosis (vs. control) 261.613 <0.001 181.191 342.035
VEGF model: CM diagnosis (vs. EM) 13.837 0.859 -141.643 169.318
Sensitivity NGF model: CM diagnosis (vs. EM) 18.855 0.017 3.455 34.256

*Quantile regression (quantile= 0.5 [median]). All models adjusted for age (continuous), sex (binary), and BMI (continuous). EM/CM/control diagnosis as categorical variable

**NGF: nerve growth factor; BDNF: brain-derived neurotrophic factor; PGE2: prostaglandin E2; VEGF: vascular endothelial growth factor; CI: confidence interval; EM: episodic migraine; CM: chronic migraine

*** Sensitivity model also adjusted for non-steroidal anti-inflammatory drug usage (binary) and beta blocker drug usage (binary)